Innovation Ventures Search Results

A Next-Generation, Non-Viral, Non-Lipid Gene Therapy Platform for Cystic Fibrosis & Beyond

A novel non‑viral, non‑lipid delivery system enables safe transfer of large genetic payloads, avoiding key limits of current gene therapies and improving uptake using targeted siRNA or drug-based enhancers.

Autologous cell and gene therapy for Gaucher Disease

Therapy for neuronopathic Gaucher Disease using gene therapy and a specialized neuronal lineage iPS cell that facilitates entry to and engraftment in the brain.

Bivalent VLP Ebola Vaccine

Bi-valent spherical virus like particle (VLP) vaccine against Ebola virus.

Combination Therapy for Leukemia and Solid Tumors

A pharmaceutical therapy that has demonstrated, in vivo, the ability to eliminate leukemic, lung adenocarcinoma and lung squamous carcinoma cells.

Methods for treating inflammation and autoimmune disease.

Microbiota-derived retinoid boosts immunity

Probiotic bacteria strains increase infection resistance.

Norovirus P Particle Vaccine Development Platform

This technology utilizes the Norovirus P particle as a platform for the development of novel vaccines.

Novel DUSP1 and FLT3-JAK2-IKK1 Degraders for Treating Relapsed and Recurrent Leukemia

Next-generation orally bioavailable degrader programs targeting DUSP1 and NFKB1 suppress JAK-STAT and NFκB signaling to restore treatment sensitivity in relapsed and refractory leukemia and potentially other cancers.

Novel Small Molecule RAC-Pathway Inhibitor for the Treatment of Cancer

Our proprietary inhibitor binds to VAV3 thereby inhibiting the activation of RAC downstream of several oncogenes.

Pseudotyped Lentiviral Vector for Duchenne Muscular Dystrophy (DMD)

Engineered lentiviral platforms leveraging Myomaker/Myomerger-mediated muscle targeting overcome key limitations, enabling delivery of large genetic payloads with the potential for reduced immunogenicity and repeat dosing in muscular dystrophies.

Rapid reliable method for collection of keratinocyte RNA and DNA samples from children.

Rapid reliable method for collection of keratinocyte RNA, DNA, microbiome, proteins, lipids, and metabolites.

Rotavirus Subunit Vaccine Based on Norovirus S Particle Platform

A non-replicating subunit Rotavirus vaccine was developed by using a novel S particle platform and displaying recombinant antigens.

Small Molecule Inhibitors for Treating Demyelinating Diseases

Small molecules, targeting HDAC3, enhance myelin repair in demyelinating diseases and injuries

Stem Cell & Organoid Medicine

Organoids provide an unprecedented opportunity to study human organ development and physiology, and investigate the cause of disease.

Synaptometric

Synaptometric uses translational EEG biomarkers to bridge preclinical and clinical development, helping reduce risk in CNS drug development programs.

Targeted inhibition of UBE2N as a therapeutic approach in myeloid malignancies

Pharmacologic and genetic inhibition of UBE2N suppresses the function and viability of MDS/AML cells lines and patient samples. A commercially available and a novel compound has been identified.

Targeting NTRK1 for Treatment of Allergic Inflammatory Conditions

Pharmacological targeting of NTRK1 using small molecule inhibitors may reduce allergic inflammation.

Therapeutic Inhibition of the WT1-MYCN-PLK1 Axis for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Repurposing Volasertib, a potent PLK1 inhibitor, as a treatment of Idiopathic Pulmonary Fibrosis

Therapeutic Prevention of Obesity in At-Risk Populations

A method to prevent or treat diet-induced obesity and/or the associated co-morbidities in an at-risk population.

Therapeutic Protein Delivery Across the Blood-Brain Barrier

A delivery mechanism which allows large molecule therapeutics to trancytose the blood-brain barrier for treatment of neurological disorders.

Thrombin Inhibitor as Novel Oral Treatment for Atopic Dermatitis

A newly established link between the mechanistic role of thrombin and fibrinogen and their contribution to AD provides a novel mechanism for oral treatment.

Using Dantrolene to Treat Neuronopathic Gaucher Disease

Dantrolene is an antagonist of ryanodine receptors (Ryrs) and blocks Ryr-mediated endoplasmic reticulum calcium release. It is an FDA-approved drug.

Innovation Ventures
Innovation Ventures Search Results

Results (22)